In May, the ACLU announced that it was suing to invalidate a patent that covers testing for genetic variants associated with breast cancer. The suit targeted Myriad Genetics, which licenses the patent, and the University of Utah officials that licensed it to them, but also targets the US Patent and Trademark Office, which allowed this form of gene patent in the first place. In a move that surprised no one, each of the three defen....
Ars Technica
